VB10.2129 / Nykode Therap - LARVOL DELTA

A novel SARS-CoV-2 Beta RBD DNA vaccine directly targeted to antigen-presenting cells induces strong humoral and T cell responses. (PubMed, Sci Rep) - "Immunogenicity studies in mice demonstrated that the APC-targeted vaccine induced strong antibody responses to both homologous Beta RBD and heterologous RBDs derived from Wuhan, Alpha, Gamma, Delta, and Omicron BA.1 variants, as well as cross-neutralizing antibodies against these VoC. Overall, preclinical data justify the exploration of VB2129 as a potential booster vaccine that induces broader antibody- and T cell-based protection against current and future SARS-CoV-2 VoC."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Phase 1/2 Study to Determine Safety and Immunogenicity of Two COVID 19 Vaccines VB10.2129 (RBD Candidate) and VB10.2210 (T Cell Candidate) Previously Vaccinated in Healthy Adult Volunteers (clinicaltrials.gov) - P1/2 | N=68 | Completed | Sponsor: Nykode Therapeutics ASA | Active, not recruiting ➔ Completed | N=160 ➔ 68 | Trial completion date: Oct 2023 ➔ May 2023

Enrollment change • Trial completion • Trial completion date • Infectious Disease • Novel Coronavirus Disease

A Phase 1/2 Study to Determine Safety and Immunogenicity of Two COVID 19 Vaccines VB10.2129 (RBD Candidate) and VB10.2210 (T Cell Candidate) Previously Vaccinated in Healthy Adult Volunteers (clinicaltrials.gov) - P1/2 | N=160 | Active, not recruiting | Sponsor: Nykode Therapeutics ASA | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease